.svg?iar=0&hash=F6049510E33E4E6D8196C26CCC0A64A4){kind=logo}
/hfh-logo-main--white.svg?iar=0&hash=ED491CBFADFB7670FAE94559C98D7798){kind=logo}
Atopic Dermatitis Research Project
A Collaborative Effort by Henry Ford Health, Premier Inc., and Eli Lilly and Company
Transforming Atopic Dermatitis Care
Atopic dermatitis (AD), the most common form of eczema, is a chronic skin condition causing intense itching, redness, pain, and burning. It affects over 16.5 million adults and 9.6 million children in the U.S., disrupting daily life, mental health, and well-being, especially for those with moderate to severe symptoms.
Disparities in care access, particularly in underserved communities, make managing AD challenging. Henry Ford Health partnered with Premier Inc., with funding from Eli Lilly and Company, for a qualitative study in Detroit targeting underserved populations. Through in-depth interviews with patients and clinicians, the study uncovered barriers to care, treatment challenges, and socioeconomic factors, offering insights to improve AD care and health equity.
Key Findings
Economic Burden
Out-of-pocket costs for AD management range from $600 to $5,000 annually, creating a financial burden.
Access Challenges
Long wait times, high costs, and insurance limits hinder care, especially for underserved communities.
Racial Disparities
- African American patients often face more severe atopic dermatitis.
- They are underrepresented in AD clinical research.
- Some experience clinician bias, causing misdiagnosis or poor treatment.
Systemic Barriers
- Inadequate PCP Training: Patients in underserved areas rely on primary care providers (PCPs) who often lack training to diagnose and manage AD.
- Prior Authorization Delays: Insurance prior authorization delays access to treatments like biologics, forcing patients with limited resources to use less effective options.
Mental Health Impact
66% of AD patients report negative mental health effects, feeling isolated and insecure due to visible symptoms.
Act to Improve AD Care
Read the white paper to understand barriers to atopic dermatitis care and explore solutions like better specialist access, enhanced provider training, and streamlined treatment approvals.